AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04033445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo IV or SC.
Trial: NCT02260674
Drug: JNJ-54861911, 10 milligram (mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
Trial: NCT02260674
Drug: JNJ-54861911, 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
Trial: NCT02260674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
Trial: NCT03375697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo intravenously.
Trial: NCT02048813
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00043407
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
Trial: NCT06801886
Drug: Silymarine supplementation
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of silymarin supplementation daily during the early post-transplant period, (for 30 days) under standard treatment.
Trial: NCT04098068
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 (pembrolizumab) 200 mg flat dose every 21 days
Trial: NCT00646763
Drug: G-CSF, GM-CSF administered at extremities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
Trial: NCT03733314
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011, infusion, intravenously.
Trial: NCT03733314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, infusion, intravenously.
Trial: NCT04451187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.
Trial: NCT00385697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IV dosing for 14 days, repeated at Week 26
Trial: NCT01031186
Drug: GSK356278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK356278
Trial: NCT01031186
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLACEBO
Trial: NCT00236483
Drug: tramadol hydrochloride + acetaminophen
RxNorm normalized name: acetaminophen / tramadol hydrochloride Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03151993
Drug: Recombinant staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Trial: NCT02864407
Drug: Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dose for adults is 5 microgram Tiotropium and 5 microgram Olodaterol given as two puffs from the Respimat® inhaler once daily at the same time of the day.
Trial: NCT03106935
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
Trial: NCT00989313
Drug: Lesion count
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Trial: NCT03871829
Drug: Dara-SC 1800 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dara-SC 1800 mg will be administered by SC injection.
Trial: NCT00014222
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75, 600 and 830 mg/m2
Trial: NCT00014222
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2
Trial: NCT01998958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
Trial: NCT04223349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo in capsule will be administered orally.
Trial: NCT00014222
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg/m2
Trial: NCT01961921
Drug: ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01136798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
Trial: NCT02134899
Drug: Calcineurin inhibitors maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment
Trial: NCT03100136
Drug: [11C]PF-06809247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET Tracer
Trial: NCT01395914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02371161
Drug: R-DHAP/R-ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DHAP/R-ICE 3 cycles every 21 days:~1. R-DHAP~   * Rituximab 375 mg/m2, e.v. day 1~  * Desamethasone 40 mg days 1-4~  * cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~  * Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~2. R-ICE~   * Rituximab 375 mg/m2, e.v. day 1~  * Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~  * Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~  * Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM
Trial: NCT02863913
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Trial: NCT04512898
Drug: Triple therapy for H.pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of proton pump inhibitors, clarithromycin and metronidazole.
Trial: NCT04088864
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard derivative alkylating agent
Trial: NCT00053768
Drug: EPOCH regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00053768
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00053768
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01998971
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
Trial: NCT01137123
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
Trial: NCT01708005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
Trial: NCT01211756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU BID for one week, followed by 40 IU BID for 3 weeks.
Trial: NCT04445519
Drug: NCX 470 0.065% (initial phase of trial)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
Trial: NCT04445519
Drug: NCX 470 0.1% (initial phase of trial)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX 470 Ophthalmic Solution, 0.1%
Trial: NCT04445519
Drug: NCX 470 0.1% (remainder of trial)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCX 470 Ophthalmic Solution, 0.1%
Trial: NCT00686088
Drug: PRX302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
Trial: NCT04343859
Drug: IMMH-010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.
Trial: NCT04972539
Drug: AJU-A51 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose AJU-A51(Dapagliflozin/Linagliptin) 10 mg / 5 mg FDC tablet
Trial: NCT04972539
Drug: A51R1 Tab. and A51R2 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose A51R1(Dapagliflozin) 10 mg tablet and A51R2(Linagliptin) 5 mg tablet taken together
Trial: NCT03529084
Drug: EFG816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be administered orally daily.
Trial: NCT00953199
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
Trial: NCT02453516
Drug: epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug indicated to prolong the action of regional anesthesia
Trial: NCT00404599
Drug: simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40mg once a day
Trial: NCT04030988
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
Trial: NCT04328337
Drug: Intralipid, 20% Intravenous Emulsion
RxNorm normalized name: Intralipid, 20% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Intralipid 20%
Trial: NCT04328337
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 30 ml/hr for 12 hours through an IV
Trial: NCT02551692
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches.
Trial: NCT04344756
Drug: Tinzaparin or unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days
Trial: NCT00496834
Drug: Comparator: losartan (+) hydrochlorothiazide (HCTZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Trial: NCT00496834
Drug: Comparator: carvedilol (+) hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Trial: NCT02538679
Drug: US TAP Bupivacaine/Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Trial: NCT02538679
Drug: Lap TAP Bupivacaine/Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
Trial: NCT00729690
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
Trial: NCT00345787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding placebo is applied for 12weeks
Trial: NCT03655522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There were two Placebos per group.
Trial: NCT04248465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Trial: NCT00609323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment of up to 400 cm2 Cream applied for 60 minutes.
Trial: NCT00522678
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
Trial: NCT00522678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive Placebo matching GW685698X via DISKUS.
Trial: NCT00169962
Drug: rhDNAse (pulmozyme)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02432703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
Trial: NCT01529190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02746237
Drug: KAR5585 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple ascending doses of KAR5585 (100 mg initial dose)
Trial: NCT02746237
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple ascending doses of placebo (100 mg initial dose)
Trial: NCT00655369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo daily dose, 3 capsules per dose during a six week treatment period.
Trial: NCT03166397
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
Trial: NCT03194945
Drug: CSII followed by Lina+MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
Trial: NCT03194945
Drug: CSII followed by Lina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
Trial: NCT03194945
Drug: CSII followed by MET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
Trial: NCT03194945
Drug: CSII alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No OHA is given after short-term intensive CSII
Trial: NCT02585141
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
Trial: NCT06632834
Drug: simvastatin therapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin should be administered initially with the dose of 10 mg once daily for adult and 0.25 mg/Kg once daily for children. Dose of simvastatin will be increased to the dose of 20 mg once daily for adult and 0.5 mg/Kg once daily for children after the check at 3 months without adverse effects.
Trial: NCT01106014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching selexipag
Trial: NCT04382768
Drug: Inhaled Hypertonic ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard of care plus lipid ibuprofen 50mg tid
Trial: NCT04442737
Drug: D/C/F/TAF FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
Trial: NCT04442737
Drug: TAF/FTC FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF/FTC ARV regimen will be administered once daily.
Trial: NCT04442737
Drug: INI Based Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
Trial: NCT00687739
Drug: Estradiol Transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.075 mg patch per day for 5 months
Trial: NCT02133001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
Trial: NCT03629951
Drug: Oral Antipsychotics (OAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
Trial: NCT03153137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet; oral use
Trial: NCT04261023
Drug: Orencia 125 MG Per 1 ML Prefilled Syringe
RxNorm normalized name: Orencia 125 MG per 1 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept sub-cutaneous injection 125mg at week 0 and once weekly thereafter for a maximum of 48 weeks
Trial: NCT04216524
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04216524
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04216524
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04216524
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, or PO
Trial: NCT02072278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02734004
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736
Trial: NCT01580995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily
Trial: NCT01190930
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV